Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4496249 | 0.92 | KCNH2 (0.51) | ALDH1A1KCNH2MAPTACHESLC6A4 | |
| SCHEMBL4501410 | 0.81 | ALDH1A1 (0.62) | ALDH1A1KCNH2MAPTDRD2DRD4 | |
| Hydrochloric Acid SCHEMBL10410496 | 0.80 | ALDH1A1 (0.61) | ALDH1A1KCNH2MAPTDRD2DRD4 | |
| SCHEMBL16682352 | 0.79 | KCNH2 (0.60) | KCNH2MAPTACHESLC6A4 | |
| SCHEMBL991681 | 0.78 | KCNH2 (0.54) | KCNH2MAPTACHESLC6A4 | |
| SCHEMBL6643236 | 0.77 | ALDH1A1 (0.68) | ALDH1A1KCNH2MAPTKDM4ETDP1 | |
| SCHEMBL6181736 | 0.76 | KCNH2 (0.57) | ALDH1A1KCNH2MAPTACHESLC6A4 | |
| SCHEMBL30849521 | 0.76 | KCNH2 (0.50) | KCNH2MAPTACHE | |
| SCHEMBL4480987 | 0.75 | TDP1 (0.45) | ALDH1A1KDM4ETDP1 | |
| SCHEMBL6247395 | 0.75 | KCNH2 (0.56) | KCNH2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442698-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2008-10-28 | — | — | US | disclosed |
| EP-1648464-A1 | 2-AMINO-4-HYDROXY-5-PYRIMIDINCARBOXAMID DERIVATIVES AND RELATED COMPOUNDS AS T-CELL ACTIVATION INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS | AMGEN INC. (US) | 2006-04-26 | — | — | EP | disclosed |
| US-20050026914-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-02-03 | — | — | US | disclosed |
| WO-2005009443-A1 | 2-AMINO-4-HYDROXY-5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF T CELL ACTIVATION FOR THE TREATMENT OF INFLAMMATORY DISEASES | AMGEN INC. (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026914-A1 | Substituted heterocyclic compounds and methods of use | NFATC1, ICOS, BET1 | ALDH1A1 370/4885KCNH2 2422/4885MAPT 1512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.